DEA Slaps Seven Deadly Opioids into Schedule I Lockdown
Published Date: 10/15/2025
Rule
Summary
Starting October 15, 2025, the DEA is temporarily putting seven powerful new opioids into Schedule I, meaning they’re considered very dangerous with no accepted medical use. This affects anyone who makes, sells, studies, or even possesses these drugs, who will now face strict rules and penalties. The temporary ban lasts two years, giving the government time to keep people safe while deciding what’s next.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Seven Nitazenes Placed in Schedule I
Starting October 15, 2025, DEA temporarily places seven benzimidazole-opioids (ethyleneoxynitazene; methylenedioxynitazene; 5-methyl etodesnitazene; N-desethyl etonitazene; N-desethyl protonitazene; N,N-dimethylamino etonitazene; and N-pyrrolidino isotonitazene) in Schedule I through October 15, 2027 (with a possible one-year extension). Schedule I means these substances are treated as having high potential for abuse and no accepted medical use and are subject to Schedule I controls and sanctions.
Unauthorized Possession and Retail Sales Outlawed
Possessing any quantity of these seven substances in a manner not authorized by the Controlled Substances Act on or after October 15, 2025 is unlawful and may subject you to administrative, civil, and criminal sanctions; retail sales of Schedule I controlled substances to the general public are not allowed under the CSA.
Registration Required to Handle These Drugs
As of October 15, 2025, anyone who handles (manufactures, distributes, imports/exports, researches, analyzes, or possesses) these seven substances must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. Persons currently handling these substances who are not registered must submit an application and may not continue to handle them unless DEA approves the registration.
Surrender or Dispose Stocks If Not Registered
If you possess any of these seven substances and do not want or cannot obtain a Schedule I registration, you must surrender all currently held quantities; you may not continue to lawfully hold them after October 15, 2025. The temporary order requires disposal or surrender of stocks by persons who will not be registered.
Immediate Security, Labeling, Inventory, and Reporting Rules
Beginning October 15, 2025, registrants handling these substances must meet Schedule I security requirements (21 CFR 1301.71-1301.93), labeling and packaging rules, take required inventories (initial inventory and biennial thereafter), maintain records, and submit reports and order forms as specified in 21 U.S.C. and 21 CFR parts (with current registrants given 30 calendar days from October 15, 2025 to comply with labeling, inventory, and recordkeeping requirements).
Manufacture Limited to DEA-Registered Quota Holders
Only DEA-registered manufacturers may lawfully manufacture these seven substances, and manufacturing is limited to quotas assigned under 21 U.S.C. 826 and 21 CFR part 1303, effective October 15, 2025. Manufacturers must comply with quota, order form, import/export, and reporting requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-19537, Fisheries of the Exclusive Economic Zone Off Alaska; Atka Mackerel in the Bering Sea Subarea and Eastern Aleutian District of the Bering Sea and Aleutian Islands Management Area
Starting October 9, 2025, fishing boats in the Bering Sea and Eastern Aleutian District have to stop catching Atka mackerel because they’ve hit their 2025 limit. This temporary closure helps protect the fish and keeps the fishing fair for everyone involved. The rule lasts until the end of 2025 and mainly affects trawl fishing vessels in the area.
Next: 2025-19554, Airworthiness Directives; Airbus Helicopters
If you own or fly an Airbus H160-B helicopter, listen up! The FAA found some broken parts in the main gearbox supports and now requires regular checks for cracks and fixes if needed. Starting October 30, 2025, you can’t install certain parts unless they meet new safety rules—so get ready to inspect, fix, and keep flying safe without breaking the bank.